ICH Quality Guideline · Biotechnology Viral Safety

ICH Q5A(R2): Viral Safety Evaluation of Biotechnology Products

Q: Does Q5A(R2) cover continuous manufacturing?

Yes. Section 7 provides viral-safety considerations specific to continuous manufacturing and should be read with ICH Q13.

Q: Are in vivo virus assays still mandatory for CHO cell lines?

No. In vivo testing is not necessary for extensively used, well-characterised cell lines such as CHO, NS0, and SP2/0 when supported by prior knowledge and risk assessment.

Q: What should be included in the regulatory viral-safety package?

The application should explain and justify the complete viral-safety strategy, including cell-substrate and raw-material testing, production-stage testing, viral-clearance evaluation, risk assessments, and an overall summary.

ICH Q5A(R2) is the current ICH guideline for evaluating viral safety in biotechnology products derived from human or animal cell lines. Adopted at Step 4 on 1 November 2023, it updates the long-standing Q5A framework to reflect modern biotechnology products, advanced manufacturing, improved virus-detection technology, broader use of risk-based approaches, and accumulated experience with viral-clearance validation. The guideline retains the core principle that viral safety cannot be demonstrated by a single test. Instead, confidence is built through a complementary strategy: selecting and testing cell substrates and raw materials, demonstrating the capacity of the manufacturing process to remove or inactivate viruses, and testing at appropriate stages of production. Q5A(R2) also introduces or expands guidance on Next Generation Sequencing (NGS), nucleic acid amplification techniques, prior knowledge and platform validation, continuous manufacturing, resin reuse, well-characterised rodent cell substrates, and certain genetically engineered viral vectors and viral-vector-derived products. This article explains the guideline in practical terms for pharmaceutical and biotechnology professionals while separating source-derived expectations from added educational context.

Featured-snippet definition: ICH Q5A(R2) is the harmonised ICH guideline that describes how biotechnology manufacturers should evaluate, control, test, and demonstrate viral safety for products derived from human or animal cell lines.

What Is ICH Q5A(R2)?

ICH Q5A(R2), titled Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin, describes the evaluation of viral safety, including viral testing and viral clearance, and outlines the data expected in marketing applications for products within scope.

The revision was adopted on 1 November 2023. It retains the fundamental scientific structure of Q5A(R1) but modernises the guideline for new product types, new analytical methods, platform manufacturing knowledge, and continuous manufacturing.

Q5A(R2) should be viewed within the broader ICH Quality Guidelines framework. The ICH Step 4 training material specifically notes that it should be read with ICH Q2, ICH Q5D, and ICH Q13.

Why Was ICH Q5A Revised?

The original Q5A framework remained scientifically valuable, but the biotechnology landscape changed substantially after its earlier revision. The Q5A(R2) concept paper identified several gaps: new biotechnology product classes, limited treatment of modern viral-clearance validation approaches, new virus-detection methods such as PCR and NGS, and the need for viral-safety guidance for advanced and continuous manufacturing.

The revision also sought to reduce divergent regional expectations. The business plan noted that without an updated global guideline, companies could face multiple filing strategies, inconsistent implementation of new technology, and additional regulatory complexity.

Major Q5A(R2) update	What changed	Practical significance
New product types	Expanded treatment of certain genetically engineered viral vectors and viral-vector-derived products that are amenable to viral clearance.	Brings newer platforms such as some AAV, VLP, subunit, and nanoparticle-based products into a harmonised viral-safety framework.
NGS and molecular methods	NGS and NAT/PCR are formally integrated into virus-testing strategy.	Supports broader detection, reduced animal use, and replacement of selected traditional assays where justified.
Prior knowledge	New Section 6.6 and Annex 5 provide principles and examples for platform validation.	Can reduce product-specific viral-clearance studies when process understanding and comparability are strong.
Continuous manufacturing	New Section 7 addresses CM-specific viral-safety considerations.	Extends viral-safety principles to integrated, connected, and longer-duration operations.
Resin reuse	Prior knowledge is explicitly recognised for end-of-life Protein A resin and potentially other chromatography types.	May reduce unnecessary product-specific end-of-life viral-clearance studies.
Well-characterised cell lines	More flexibility for well-characterised rodent cell substrates such as CHO, NS0, and SP2/0.	Supports risk-based omission or replacement of some legacy animal tests.

Scope of ICH Q5A(R2)

The guideline applies to biotechnology products derived from cell lines of human or animal origin, including mammalian, avian, and insect systems. Examples include cytokines, monoclonal antibodies, recombinant proteins, and subunit vaccines produced using in vitro cell culture.

The revised scope also includes certain genetically engineered viral vectors and viral-vector-derived products when they are amenable to viral clearance without negatively affecting the product. Examples described in the guideline include some AAV products, baculovirus-expressed VLPs, protein subunits, and nanoparticle-based protein vaccines and therapeutics.

Products excluded from scope

Inactivated viral vaccines.
Live attenuated viral vaccines containing self-replicating agents.
Cell therapies, although relevant principles may be applied to biological starting or raw materials where appropriate.
Nonconventional transmissible agents such as mammalian prions; these should be addressed with the appropriate regulatory authority.

Implementation nuance: The Step 4 presentation states that general considerations and approaches may still be useful for products outside the formal scope, but this does not convert those products into Q5A(R2)-in-scope products.

The Three Complementary Viral-Safety Controls

Q5A(R2) is built around three complementary approaches rather than reliance on one analytical result.

1. Control the starting systemSelect and test cell lines, cell banks, raw materials, reagents, and media components for undesirable infectious viruses.

2. Demonstrate viral clearanceAssess the ability of the production and purification process to remove and/or inactivate adventitious and endogenous viruses.

3. Test during productionTest at appropriate manufacturing stages to demonstrate absence of contaminating infectious viruses.

This layered strategy reflects a central Q5A principle: direct testing alone cannot establish viral safety because low-level contamination may escape detection statistically. Confidence is strengthened by combining testing with a well-characterised process that has demonstrated virus-removal and inactivation capability.

Potential Sources of Viral Contamination

Viruses associated with the cell substrate

Viruses may be present because of the original source of the cell line, use of a virus in establishing the cell line, contaminated biological reagents, contaminated raw materials, or contamination introduced during cell handling and banking. Endogenous retroviral sequences may also be present, and latent or persistent viruses may occur in some cell substrates.

Adventitious viruses introduced during manufacture

Q5A(R2) identifies potential entry routes including contaminated serum or other biological raw materials, contaminated virus seeds, downstream purification reagents such as animal-derived affinity materials, contaminated excipients, and environmental or personnel-related contamination.

The guideline recommends avoiding human- and animal-derived raw materials when possible. Where they are needed, qualification should be commensurate with risk and may include origin, tissue source, virus testing, and any inactivation or removal measures applied to the material.

Viral Safety Evaluation of Biotechnology Products

Cell-Line Qualification and Virus Testing

Qualification of the production cell substrate is a foundational element of Q5A(R2). Testing is organised around the Master Cell Bank (MCB), Working Cell Bank (WCB), and cells at the Limit of In Vitro Cell Age (LIVCA), also referred to as End of Production Cells (EOPC) in relevant contexts.

Stage	Key Q5A(R2) expectation	Purpose
MCB	Extensive screening for endogenous and adventitious viruses using broad and specific detection approaches based on risk.	Characterises the foundational production cell bank.
WCB	Adventitious virus testing is expected, although some testing can be omitted when justified by MCB and LIVCA testing.	Confirms the working production bank remains appropriately controlled.
LIVCA / EOPC	One-time evaluation for viruses that might have escaped earlier detection, become induced, reactivated, or amplified during extended culture.	Demonstrates that production-age cells do not introduce additional viral risk.

Retrovirus testing

Cell lines should be characterised for retroviruses. Depending on the cell system, testing may include infectivity assays, reverse-transcriptase activity assays, and transmission electron microscopy (TEM). Q5A(R2) recognises that some established cell lines produce non-infectious retroviral-like particles and should be assessed using the totality of available data and risk.

In vitro infectivity assays

Traditional in vitro assays use multiple indicator cell lines to detect a broad range of viruses. For cell-bank qualification, the guideline describes 28-day testing with at least one sub-passage at two weeks. NGS or other molecular methods may supplement or replace these assays when suitable for their intended purpose.

In vivo assays and the 3Rs approach

In vivo testing is now explicitly risk-based. Q5A(R2) states that it is not necessary for extensively used, well-characterised cell lines such as CHO, NS0, and SP2/0 when supported by prior knowledge. If residual risk remains, non-targeted NGS may be considered as a replacement.

Next Generation Sequencing and Molecular Methods

One of the most significant changes in ICH Q5A(R2) is formal recognition of molecular methods, including nucleic acid amplification techniques such as PCR and Next Generation Sequencing.

Method	Potential Q5A(R2) role	Important limitation or condition
PCR / NAT	Virus-specific detection; may supplement cell-culture assays or replace selected virus-specific animal-based tests.	Detects nucleic acid and does not by itself demonstrate infectivity.
Targeted NGS	Detection of known viruses or specific virus groups.	Requires suitable sequence information and an appropriate validated/qualified workflow.
Non-targeted NGS	Broad detection of known, unexpected, or novel viral sequences; may replace in vivo testing and supplement or replace in vitro assays.	Positive signals require investigation; detected nucleic acid may not represent infectious virus.

Q5A(R2) specifically states that a head-to-head comparison with legacy in vivo or in vitro assays is not recommended when NGS is used as a suitable replacement, because the endpoints and breadth of detection differ. The guideline treats NGS as a limit test and directs validation or qualification toward the principles of ICH Q2.

What a robust NGS workflow should consider

Sample pretreatment and virus enrichment, where needed.
Efficiency of viral nucleic acid extraction.
Library preparation for DNA and RNA viruses.
Sequencing platform selection.
Bioinformatic analysis against a comprehensive viral database.
Reference materials demonstrating sensitivity, specificity, and breadth.
Follow-up investigation of virus-specific signals.
Matrix-specific verification and validation/qualification appropriate to intended use.

Testing for Viruses in Unprocessed Bulk

Q5A(R2) recommends routine adventitious-virus testing of production batches at the unprocessed bulk stage. This is a particularly informative point in the process because the material is sampled before downstream purification removes or inactivates potential contamination.

For batch manufacture, unprocessed bulk may consist of one or more pooled harvests. For continuous or perfusion processes, pooled intermediate samples or samples from a continuous flow stream may be used. The sampling strategy should be justified because endogenous and adventitious virus levels may change over the duration of cell culture.

Testing may include in vitro indicator-cell assays or non-targeted NGS. The guideline also allows NAT or targeted NGS for specific virus or virus-family risks. If an adventitious virus is detected, the harvest generally should not be used for product manufacture unless justified, and the contamination source and extent should be investigated.

Continuous manufacturing point: Final release should include documented absence of viral contamination for the period in which cultivation fluid used for that batch was harvested. A segregation strategy should exist if contamination is detected.

Viral-Clearance Strategy Under ICH Q5A(R2)

Viral-clearance evaluation is central to the guideline. Studies should assess the capacity of selected process steps to remove viruses physically and/or inactivate viral infectivity, and they should estimate the overall reduction achieved by the manufacturing process.

Relevant, specific model, and non-specific model viruses

Relevant virus: an identified virus, or the same species as a virus known or likely to contaminate the cell substrate, reagent, or process.
Specific model virus: a closely related substitute used when the relevant virus is unavailable or unsuitable for high-titre clearance studies.
Non-specific model virus: a virus selected to represent different physicochemical properties and challenge the robustness of the process.

Generally, the guideline recommends assessing the process for its ability to clear at least three viruses with different characteristics. Resistant non-enveloped viruses deserve particular attention when characterising process robustness.

Case-based action plan

Case	Situation	Core implication
A	No virus or virus-like/retrovirus-like particle detected other than the intended product.	Characterise clearance with non-specific model viruses.
B	Rodent cell line contains only rodent retrovirus/RVLP.	Add a specific model such as MLV; established well-characterised cell lines can use accumulated prior knowledge.
C	Detected virus with no evidence of human infectivity.	Use the identified virus or appropriate relevant/specific model virus and demonstrate effective clearance.
D	Virus infectious to humans is identified.	Product is acceptable only in exceptional circumstances and requires strong targeted clearance and detection evidence.
E	Virus cannot be classified by available methods.	Product is usually considered unacceptable unless exceptional, well-justified circumstances are discussed with regulators.
F	A production virus/helper virus is deliberately used in manufacture.	Demonstrate clearance using the production virus or a suitable specific model and confirm absence of residual production virus as required.

Design of Viral-Clearance Studies

Separate virology facility

Q5A(R2) states that unintended viruses should not be introduced into a production facility. Viral-clearance studies should therefore be conducted in a separate laboratory suitable for virological work, with virology expertise and appropriate process knowledge.

Representative scale-down models

The scale-down model should represent the commercial process as closely as possible. Relevant parameters may include column bed height, linear flow rate, contact time, pH, temperature, conductivity, resin type, buffer composition, and product concentration. Worst-case conditions can be useful for demonstrating robustness.

Step-wise clearance

Process steps that are expected to contribute meaningfully to virus reduction should be evaluated individually. The guideline recommends reproducible clearance in at least two independent experiments unless a reduced study design is justified through prior knowledge.

Inactivation kinetics

Viral inactivation is often biphasic rather than simple first-order kinetics. Inactivation studies should therefore include multiple time points and an inactivation curve. At least one time point shorter than the minimum commercial exposure time and greater than zero is recommended in addition to the minimum exposure time.

Interpreting reduction factors

Effective clearance depends on the totality of the evidence, including virus choice, study design, reduction achieved, inactivation kinetics, process-parameter variation, and assay sensitivity. Q5A(R2) notes that an effective dedicated step often provides reproducible reduction on the order of 4 log₁₀ or more, while reproducible 1–3 log₁₀ reductions can still contribute to the overall safety assessment. Reductions below 1 log₁₀ are generally considered negligible unless justified.

Whenever feasible and compatible with the product, the guideline recommends two complementary viral-clearance steps with different modes of action, including one effective against non-enveloped viruses.

Prior Knowledge and Platform Validation

Q5A(R2) significantly expands the ability to use prior knowledge. Section 6.6 and Annex 5 explain when viral-clearance data from related products and platform processes may reduce the need for product-specific studies.

Prior knowledge may include published literature and in-house experience, but its applicability must be justified. Key considerations include understanding the clearance mechanism, critical process parameters, product-virus interactions, process-intermediate composition, and the limitations of the underlying clearance studies.

Platform example	Q5A(R2) perspective
Protein A resin reuse	Prior knowledge indicates that virus removal is not adversely affected and may slightly increase with used/end-of-life Protein A resin; product-specific used-resin viral-clearance studies are not expected.
Other chromatography resins	Prior knowledge may also be applied where equivalent evidence and detailed justification support the approach.
Solvent/detergent or detergent inactivation	Annex 5 provides platform examples and highlights critical parameters such as detergent concentration, time, temperature, and appropriate clarification of the intermediate.
Low-pH inactivation	Prior knowledge can support platform validation where key conditions such as pH, time, temperature, buffer matrix, and ionic strength are well understood.
Virus filtration	Platform data can be used, but Q5A(R2) describes a confirmatory product-specific run with parvovirus when prior knowledge is used to claim parvovirus removal.

Important limitation: Prior knowledge is not an automatic waiver. If similarity of processes, intermediates, or viral-clearance mechanisms is not adequately supported, product-specific viral-clearance studies should be performed.

Continuous Manufacturing and Viral Safety

Section 7 is new in Q5A(R2) and should be read alongside ICH Q13. The basic viral-safety principles remain the same as for batch manufacture, but continuous manufacturing introduces additional issues involving longer production culture, connected unit operations, material traceability, process dynamics, start-up and shutdown, monitoring frequency, and diversion or segregation of potentially affected material.

Key CM design considerations

Risk assessment of starting materials, raw materials, and extended culture duration.
Type and frequency of adventitious-virus testing.
Impact of residence-time distribution and input-material variability.
Start-up, shutdown, pauses, and transient process disturbances.
Connected chromatography operations and multi-column cycling.
Dynamic control of pH, solvent/detergent concentration, mixing, temperature, and residence time during inactivation.
Filter-change strategies and post-use integrity testing for virus filtration.

Q5A(R2) allows scientifically justified batch scale-down models to support some continuous unit operations when the commercial operating conditions are adequately represented.

Genetically Engineered Viral Vectors and Viral-Vector-Derived Products

Annex 6 is a major addition to Q5A(R2). It addresses genetically engineered viral vectors and viral-vector-derived products that are amenable to viral clearance, including products made with helper viruses or viral vectors for protein expression and products produced using stable or transient transfection.

Examples include certain AAV products, baculovirus/insect-cell-derived VLPs, recombinant protein subunits, and nanoparticle-based protein vaccines. The guideline treats production viruses as process-related impurities and applies a risk-based approach to adventitious, endogenous, production, and replication-competent virus risks.

Testing strategy for viral-vector platforms

Testing may span cell banks, master and working virus seeds, unprocessed bulk, and purified bulk/drug substance. Non-targeted NGS can replace in vivo assays and can supplement or replace in vitro assays where suitable. Replication-competent virus testing may be required at multiple stages depending on the product and risk.

Viral clearance for vector-derived products

Clearance studies should use qualified scale-down models and consider the physicochemical characteristics of the vector and product. Production virus or an appropriate specific model virus may be included, together with model viruses for adventitious and endogenous virus risks. The guideline notes that the robustness of clearance may be lower than for conventional recombinant proteins, so closed processing, testing, raw-material control, and other preventive controls can become more important.

Quality-System and Data-Integrity Considerations

Q5A(R2) should be implemented through a controlled pharmaceutical quality system. Viral-testing and viral-clearance procedures should be governed by approved SOP documents and appropriate cGMP controls.

Electronic sequencing data, viral titres, infectivity results, chromatograms, calculation worksheets, reduction factors, and investigation records should remain attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available in line with ALCOA+ principles. Where electronic records and signatures are used, applicable 21 CFR expectations should be considered.

Significant unexpected viral results, contamination events, or recurring control failures should be evaluated through the site's investigation and CAPA system.

Practical ICH Q5A(R2) Implementation Checklist

Confirm product scope. Determine whether the biotechnology product and production system fall within Q5A(R2).
Map all viral-risk sources. Review cell substrate, cell-bank history, raw materials, reagents, virus seeds, production viruses, equipment, environment, and personnel-related routes.
Define the cell-bank testing strategy. Establish MCB, WCB, and LIVCA/EOPC testing based on risk and prior knowledge.
Select suitable detection methods. Decide where infectivity assays, TEM, RT, PCR/NAT, targeted NGS, or non-targeted NGS are appropriate.
Establish unprocessed-bulk testing. Define sample composition, frequency, assay duration, and continuous-process sampling where relevant.
Build the viral-clearance strategy. Identify relevant, specific model, and non-specific model viruses and determine which process steps should be challenged.
Qualify scale-down models. Demonstrate representativeness and include worst-case conditions where appropriate.
Evaluate prior knowledge. Determine whether platform data can legitimately reduce product-specific validation effort.
Address continuous manufacturing or viral-vector-specific issues. Apply Section 7 and/or Annex 6 where applicable.
Prepare the regulatory package. Explain and justify the complete viral-safety strategy and provide an overall summary of the viral-safety assessment in the marketing application.

Key Takeaways

ICH Q5A(R2) was adopted at Step 4 on 1 November 2023.
Viral safety relies on three complementary controls: source-material/cell-line testing, process viral clearance, and testing at appropriate production stages.
The revised guideline formally integrates NGS and PCR/NAT into viral-safety testing strategy.
Non-targeted NGS can replace in vivo assays and can supplement or replace in vitro assays when suitably demonstrated for intended use.
Prior knowledge and platform validation can reduce product-specific viral-clearance studies when comparability and process understanding are sufficiently strong.
Q5A(R2) includes a dedicated continuous-manufacturing section aligned with ICH Q13.
The scope now includes certain genetically engineered viral vectors and viral-vector-derived products that are amenable to viral clearance.
Well-characterised cell substrates such as CHO, NS0, and SP2/0 can support more flexible, risk-based testing strategies.
Viral-clearance studies should use representative scale-down models, suitable virus selection, and statistically valid data.
No single test establishes viral safety; the complete control strategy and its scientific justification are essential.

Conclusion

ICH Q5A(R2) modernises the global approach to viral safety without abandoning the central principles that made Q5A foundational to biotechnology product control. The revised guideline recognises that viral safety must be demonstrated through a layered, science- and risk-based strategy rather than by a single analytical test.

Its most important advances are the integration of NGS and molecular methods, expanded use of prior knowledge and platform validation, explicit treatment of continuous manufacturing, updated flexibility for well-characterised cell substrates, and new guidance for certain genetically engineered viral vectors and viral-vector-derived products. For industry, successful implementation depends on combining these new flexibilities with strong process understanding, justified viral-clearance studies, robust cGMP controls, complete data integrity, and a clearly documented overall viral-safety assessment.

Frequently Asked Questions About ICH Q5A(R2)

1. What is ICH Q5A(R2)?

ICH Q5A(R2) is the harmonised ICH guideline for evaluating viral safety of biotechnology products derived from human or animal cell lines, including viral testing and viral-clearance evaluation.

2. When was ICH Q5A(R2) adopted?

The final Step 4 guideline was adopted on 1 November 2023.

3. What are the three main approaches to viral safety in Q5A(R2)?

They are selection and testing of cell lines and raw materials, assessment of the manufacturing process for viral clearance, and testing at appropriate production stages for contaminating infectious viruses.

4. Does Q5A(R2) allow NGS to replace traditional virus tests?

Yes. Non-targeted NGS can replace in vivo assays and may supplement or replace in vitro cell-culture assays when shown suitable for its intended use. Targeted or non-targeted NGS can also replace selected virus-specific PCR or animal antibody-production tests.

5. Is a head-to-head comparison required when replacing in vivo testing with NGS?

No. Q5A(R2) explains that head-to-head comparison is not recommended because the assays have different endpoints and NGS has broader virus-detection capability.

6. What is prior knowledge in Q5A(R2)?

Prior knowledge includes external evidence and applicant-owned in-house experience that can support viral-clearance understanding and, when adequately justified, reduce some product-specific validation work.

7. Does Q5A(R2) cover continuous manufacturing?

Yes. Section 7 provides specific viral-safety considerations for continuous manufacturing and is intended to be read with ICH Q13.

8. Does Q5A(R2) cover viral vectors?

It covers certain genetically engineered viral vectors and viral-vector-derived products that are amenable to viral clearance without negatively affecting the product. Annex 6 provides the detailed considerations.

9. Are in vivo virus assays still mandatory for CHO cell lines?

No. Q5A(R2) states that in vivo testing is not necessary for extensively used, well-characterised cell lines such as CHO, NS0, and SP2/0 when supported by prior knowledge and the overall risk assessment.

10. What should be included in the regulatory viral-safety package?

The marketing application should explain and justify the viral-safety strategy, including cell-substrate and raw-material testing, production-stage testing, viral-clearance evaluation, relevant risk assessments, and an overall summary of the studies and controls used to prevent or mitigate viral contamination.

Editorial source note: This article is an original explanatory adaptation of the ICH Q5A(R2) Step 4 guideline, the ICH Step 4 training presentation, and the supporting Q5A(R2) concept paper and business plan. Added practical QC and quality-system explanations are intended to improve usability and do not replace the official ICH guideline, regional implementation requirements, approved dossiers, or regulator advice.